Cefalotin: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Kiran Singh (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| verifiedrevid = 460022605 | |||
| IUPAC_name = (6''R'',7''R'')-3-[(acetoxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |||
| image =Cefalotin.png | |||
| width = 300 | | width = 300 | ||
| | <!--Clinical data--> | ||
| | | tradename = | ||
| | | Drugs.com = {{drugs.com|international|cefalotin}} | ||
| | | MedlinePlus = a682860 | ||
| | | pregnancy_US = B | ||
| | | pregnancy_AU = A | ||
| legal_AU = S4 | |||
| legal_UK = POM | |||
| routes_of_administration = [[Intravenous therapy|Intravenous]] | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = n/a | | bioavailability = n/a | ||
| protein_bound = 65 to 80% | | protein_bound = 65 to 80% | ||
Line 14: | Line 21: | ||
| elimination_half-life = 30 minutes to 1 hour | | elimination_half-life = 30 minutes to 1 hour | ||
| excretion = [[Kidney|Renal]] | | excretion = [[Kidney|Renal]] | ||
| | |||
| | <!--Identifiers--> | ||
| | | CASNo_Ref = {{cascite|correct|CAS}} | ||
| | | CAS_number_Ref = {{cascite|correct|??}} | ||
}} | | CAS_number = 153-61-7 | ||
__NOTOC__ | | ATC_prefix = J01 | ||
| ATC_suffix = DB03 | |||
| PubChem = 6024 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank = DB00456 | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 5802 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = R72LW146E6 | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D07635 | |||
| ChEBI_Ref = {{ebicite|correct|EBI}} | |||
| ChEBI = 124991 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 617 | |||
<!--Chemical data--> | |||
| C=16 | H=16 | N=2 | O=6 | S=2 | |||
| molecular_weight = 396.44 g/mol | |||
| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cc3sccc3)COC(=O)C)C(=O)O | |||
| InChI = 1/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1 | |||
| InChIKey = XIURVHNZVLADCM-IUODEOHRBQ | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1 | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = XIURVHNZVLADCM-IUODEOHRSA-N | |||
}}__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Cefalotin''' ([[International Nonproprietary Name|INN]]) ({{pronEng|sɛfəˈlotən/, /kɛfə-}}) or '''cephalothin''' ([[United States Adopted Name|USAN]]) ({{IPA|/sɛfəˈloθən/, /kɛfə-/}}) is a first-generation [[cephalosporin]] [[antibiotic]]. It was the first cephalosporin marketed and continues to be widely used. It is an [[intravenous]]ly-administered agent with a similar antimicrobial spectrum to [[cefazolin]] and the oral agent [[cefalexin]]. '''Cefalotin sodium''' is commonly marketed under the trade name '''Keflin''' ([[Eli Lilly and Company|Lilly]]). | '''Cefalotin''' ([[International Nonproprietary Name|INN]]) ({{pronEng|sɛfəˈlotən/, /kɛfə-}}) or '''cephalothin''' ([[United States Adopted Name|USAN]]) ({{IPA|/sɛfəˈloθən/, /kɛfə-/}}) is a first-generation [[cephalosporin]] [[antibiotic]]. It was the first cephalosporin marketed and continues to be widely used. It is an [[intravenous]]ly-administered agent with a similar antimicrobial spectrum to [[cefazolin]] and the oral agent [[cefalexin]]. '''Cefalotin sodium''' is commonly marketed under the trade name '''Keflin''' ([[Eli Lilly and Company|Lilly]]). | ||
Line 31: | Line 65: | ||
{{CephalosporinAntiBiotics}} | {{CephalosporinAntiBiotics}} | ||
[[Category:Drug]] | |||
[[Category:Cephalosporin antibiotics]] | [[Category:Cephalosporin antibiotics]] | ||
Latest revision as of 13:31, 10 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a682860 |
Pregnancy category | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | 65 to 80% |
Metabolism | Hepatic |
Elimination half-life | 30 minutes to 1 hour |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C16H16N2O6S2 |
Molar mass | 396.44 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Cefalotin |
Articles |
---|
Most recent articles on Cefalotin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Cefalotin at Clinical Trials.gov Clinical Trials on Cefalotin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Cefalotin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Cefalotin Discussion groups on Cefalotin Directions to Hospitals Treating Cefalotin Risk calculators and risk factors for Cefalotin
|
Healthcare Provider Resources |
Causes & Risk Factors for Cefalotin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cefalotin (INN) (Template:PronEng) or cephalothin (USAN) (Template:IPA) is a first-generation cephalosporin antibiotic. It was the first cephalosporin marketed and continues to be widely used. It is an intravenously-administered agent with a similar antimicrobial spectrum to cefazolin and the oral agent cefalexin. Cefalotin sodium is commonly marketed under the trade name Keflin (Lilly).